This post was originally published on this site
Investing.com – Enochian Biosciences (NASDAQ:ENOB) stock rose more than 5% in Monday’s premarket but was trading up 0.4% early in the official trading session after the Food and Drug Administration accepted the company’s request to provide feedback on its potential drug to cure Hepatitis B.
The FDA’s comments are expected this fall. A note by the company said it is on track to develop a commercial product.
The company said its pre-IND (investigational new drug) request was made based on promising data from a proof-of-concept study conducted in chimeric mice, considered by some scientific experts to be the ‘gold standard’ animal model to evaluate HBV cure.
Hepatitis can cause chronic liver damage and kills nearly 1 million people every year.
According to Mark Dybul, a prominent expert in viruses and Executive Vice Chairperson of the company’s Board, the novel mechanism, called Hijack RNA, holds promise as a potential platform technology for coronaviruses (including the cause of COVID-19), influenza and HIV as well.
